Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha

Dirican, Ahmet; Kucukzeybek, Yuksel; Erten, Cigdem; Somali, Isil; Demir, Lutfiye; Can, Alper; Payzin, Kadriye Bahriye; Bayoglu, Ibrahim Vedat; Akyol, Murat; Yildiz, Yasar; Koseoglu, Mehmet; Alacacioglu, Ahmet; Tarhan, Mustafa Oktay

추천

검색

자료유형: 학술저널

저자정보: Dirican, Ahmet (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Kucukzeybek, Yuksel (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Erten, Cigdem (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Somali, Isil (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Demir, Lutfiye (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Can, Alper (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Payzin, Kadriye Bahriye (Department of Hematology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Bayoglu, Ibrahim Vedat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Akyol, Murat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Yildiz, Yasar (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training) Koseoglu, Mehmet Alacacioglu, Ahmet Tarhan, Mustafa Oktay

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제3호

발행연도: 2013.1

수록면: 2,101 - 2,105 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Long-term survival is a problem with locally advanced and metastatic renal cell carcinomas. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, but data on sunitinib use as a second line treatment in metastatic renal cell carcinoma (mRCC) are limited. Prognostic and predictive value of peripheral blood markers has been shown for many cancers. Materials and Methods: Efficacy and safety profiles of sunitinib after interferon alpha (IFN-${\alpha}$) were evaluated based on retrospective data for 23 patients with mRCC. Hematological parameters (neutrophils, lymphocytes, platelets, mean platelet volume, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio) were recorded at the time of metastasis. It was evaluated whether hematological parameters were prognostic and predictive factors. Results: Median progression-free survival (PFS) time was 16.5 months (95%CI: 0-34.5). Median overall survival (OS) time was 25.7 months (95%CI: 10.8-40.0). Most common side effects were neutropenia (52.2%), stomatitis (26.1%) and hand-food syndrome (26.1%). PFS was found 3.13 vs 17.1 months in patients with neutrophil / lymphocyte ratio (NLR)>3 vs $NLR{\leq}3$ (p:0.012). Median OS was 6.96 vs 27.1 months in patients with NLR>3 vs $NLR{\leq}3$ (p:0.001).While 75% of patients who responded to sunitinib had $NLR{\leq}3$, in 72% of patients with no response to sunitinib NLR>3 was detected (p:0.036). The association between the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria and NLR was statistically significant (p:0.022). Conclusions: Data on second line sunitinib treatment following cytokine in mRCC are limited. In our study, we observed second line sunitinib treatment following IFN-${\alpha}$ to be effective and tolerable. NLRappeared to have prognostic and predictive value.

#Metastatic renal cell carcinoma #sunitinib #hematologic parameters

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Dirican, Ahmet

소속기관 Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital